Join

Live Feed

Delayed 3m

Press · Analyst · SEC

Signed out · 3-min delay · Sign up for real-time

  • Arcadia Biosciences Inc. logo
    PR··Consumer Staples·
    Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

    DALLAS, June 12, 2026 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc.® (NASDAQ:RKDA), a producer and marketer of innovative wellness products, announced today the closing of its previously announced private placement priced at-the-market under Nasdaq rules for the purchase and sale of 3,883,496 shares of its common stock (or pre-funded warrants in lieu thereof), Series A-1 preferred investment options to purchase up to an aggregate of 3,883,496 shares of common stock and Series A-2 preferred investment options to purchase up to an aggregate of 3,883,496 shares of common stock at a purchase price of $1.03 per share of common stock (or pre-funded warrant in lieu thereof) and associated preferr

  • Belite Bio Inc logo
    PR··Health Care·
    Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1

    SAN DIEGO, June 12, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ:BLTE) ("Belite Bio®" or the "Company"), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced the completion of its rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tinlarebant. Tinlarebant is an investigational, once-daily oral therapy for the treatment of Stargardt disease type 1 (STGD1), a rare, inherited retinal disease caused by mutations in the ABCA4 gene that leads to progressive and irreversible vision loss. STGD1 affects an estimated 53

  • Exelon Corporation logo
    PR··Utilities·
    ComEd Continues Power Restoration Following Two Powerful Storms

    Crews focus on remaining outages as weather clears across northern Illinois ComEd crews continue restoring power to customers impacted by multiple rounds of severe storms that moved through northern Illinois beginning Wednesday afternoon. With the most volatile weather now past the region, crews are focused on completing repairs and restoring service to remaining pockets of customers affected by storm damage. Multiple bands of severe weather brought intense rain, frequent lightning and high wind gusts, causing significant damage to ComEd's power infrastructure and resulting in widespread outages across the service territory. At least two tornadoes were confirmed on Thursday, including o

  • Roma Green Finance Limited logo
    PR··Consumer Discretionary·
    ROMA Green Finance Establishes Dedicated Artificial Intelligence and High-Performance Computing Infrastructure Investment Vertical

    New vertical extends ROMA's sustainable-finance mandate into energy-efficient, behind-the-meter-powered digital infrastructure; Company is evaluating a pipeline of distributed, sub-50 MW AI/HPC investment opportunities, subject to diligence, definitive documentation, and board approval. ROMA, HONG KONG, June 12, 2026 (GLOBE NEWSWIRE) -- ROMA Green Finance Limited (NASDAQ:ROMA) ("ROMA" or the "Company") today announced the establishment of a dedicated investment vertical focused on Artificial Intelligence and High-Performance Computing (AI/HPC) infrastructure. The vertical extends the Company's sustainable-finance and ESG advisory mandate into low-carbon, energy-efficient digital infrastru

  • TripAdvisor Inc. logo
    PR··Technology·
    HAMANASI ADVENTURE & DIVE RESORT, BELIZE RANKED #1 HOTEL IN CENTRAL AMERICA AND #15 IN THE WORLD IN 2026 TRIPADVISOR TRAVELERS' CHOICE BEST OF THE BEST AWARDS

    Hopkins, STANN CREEK, June 12, 2026 (GLOBE NEWSWIRE) -- Hamanasi Adventure & Dive Resort, Belize's premier luxury adventure and dive resort, proudly announces its recognition as the #1 Hotel in Central America and the #15 Best Hotel in the World in the 2026 Tripadvisor Travelers' Choice® Best of the Best Awards. Aerial view of Hamanasi Resort Treehouse rooms nestled in the coastal forest near Hopkins, Belize   The Travelers' Choice Best of the Best title celebrates the highest level of excellence in the travel industry. It is awarded exclusively to properties that receive a high volume of above-and-beyond reviews and opinions from the Tripadvisor community over a 12-month pe

  • Open Text Corporation logo
    PR··Technology·
    OpenText to Create 400 Jobs with €105 Million Investment in Cork and Galway to Expand Agentic AI and Sovereign Cloud in Europe

    Taoiseach Micheál Martin TD and CEO of IDA Ireland Michael Lohan join OpenText to announce new Cork Centre of Excellence for EMEA Investment marks the largest in Ireland by a Canadian-headquartered technology company, advancing R&D in agentic AI, sovereign cloud and cyber resilience for EMEA clientsDUBLIN, June 12, 2026 /CNW/ -- OpenText™ (NASDAQ/TSX:OTEX), a Waterloo, Ontario, Canada headquartered global leader in data management for enterprise AI, today announced a €105 million investment that will create 400 new jobs across the company's sites in Ireland over the next three years. The commitment, which doubles OpenText's investment in Ireland, will significantly expand the company's agent

  • AstraZeneca PLC logo
    PR··Health Care·
    TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer

    Based on results of CAPItello-281 which prospectively defined PTEN-deficient disease and showed TRUQAP combination reduced risk of radiographic disease progression or death by 19% First-in-class AKT inhibitor moves into second tumor type to address an aggressive form of prostate cancer associated with poor prognosis AstraZeneca's TRUQAP® (capivasertib) in combination with abiraterone and prednisone has been approved in the US as the first and only targeted treatment for adult patients with PTEN-deficient metastatic androgen pathway modulation-naïve or sensitive (mAPMN/S) prostate cancer, previously referred to as metastatic hormone-sensitive prostate cancer (mHSPC), as detected by a US

  • Whirlpool Corporation logo
    PR··Consumer Discretionary·
    Whirlpool Announces Cash Tender Offer Early Results

    BENTON HARBOR, Mich., June 12, 2026 /PRNewswire/ -- Whirlpool Corporation (NYSE: WHR) ("Whirlpool" or the "Company") is releasing early results as of 5:00 p.m., Central European time (11:00 a.m., New York City time), on June 12, 2026 (the "Early Tender Expiration"), of its previously announced (i) tender offer (the "Tender Offer") to purchase for cash any and all of the outstanding 1.250% Notes due 2026 (the "2026 Notes") and 1.100% Notes due 2027 (the "2027 Notes" and together with the 2026 Notes, the "Notes") of Whirlpool Finance Luxembourg S.à r.l., a private limited liability company (société à responsabilité limitée) organized under the laws of the Grand Duchy of Luxembourg (the "Issuer

  • BlackRock ESG Capital Allocation Term Trust logo
    PR··Finance·
    BlackRock ESG Capital Allocation Term Trust (ECAT) Announces Certified Results of 2026 Annual Shareholder Meeting

    All ECAT-Approved Trustees Will Remain in Place BlackRock Advisors, LLC ("BlackRock") announced today the final certified voting results of the 2026 Annual Meeting of Shareholders of BlackRock ESG Capital Allocation Term Trust (NYSE:ECAT) (the "Fund"). All nine of the Fund's unanimously approved nominees standing for re-election, Cynthia L. Egan, Lorenzo A. Flores, Stayce D. Harris, R. Glenn Hubbard, W. Carl Kester, John M. Perlowski, Robert Fairbairn, J. Phillip Holloman and Arthur P. Steinmetz, will continue to serve on the Board of Trustees (the "Board"). Each nominee received more support than any dissident nominee, reflecting strong shareholder support for the Board's oversight of

  • Atossa Therapeutics Inc. logo
    PR··Health Care·
    Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds

    $4.5 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon exercise in full of warrantsSEATTLE, June 12, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, today announced the closing of its previously announced registered direct offering of 1,363,637 shares (the "Shares") of its common stock, par value $0.18 per share ("Common Stock") (or common stock equivalents in lieu thereof), Series A warrants to purchase up to 1,363,637 shares of Common Stock and short-term Series B warrants to pu